People: UCB SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

63.79EUR
10 Jul 2014
Price Change (% chg)

€0.12 (+0.19%)
Prev Close
€63.67
Open
€63.41
Day's High
€65.27
Day's Low
€63.30
Volume
30,008
Avg. Vol
196,220
52-wk High
€65.27
52-wk Low
€41.56

Search Stocks

Summary

Name Age Since Current Position

Gerhard Mayr

67 2012 Non-Executive Chairman of the Board

Roch Doliveux

57 2005 Chairman of the Executive Committee, Chief Executive Officer, Executive Director

Evelyn Diego du Monceau de Bergendal

63 2006 Non-Executive Vice Chairwoman of the Board

Detlef Thielgen

54 2007 Chief Financial Officer, Executive Vice President, Member of the Executive Committee

Anna Richo

52 2013 Member of the Executive Committee, Executive Vice President and General Counsel

Fabrice Enderlin

2008 Executive Vice President - Human Resources & Communication, Member of the Executive Committee

Ismail Kola

57 2009 Executive Vice President & President UCB New Medicines, Member of the Executive Committee

Iris Loew-Friedrich

2008 Executive Vice President Biopharma Development Solutions and Chief Medical Officer, Member of the Executive Committee

Mark McDade

58 2008 Executive Vice President Established Brands, Solutions and Supply, Member of the Executive Committee

Jean-Christophe Tellier

2011 Member of the Executive Committee, Executive Vice President and President of European Operations

Arnoud de Pret Roose de Calesberg

70 2005 Non-Executive Director

Peter Fellner

71 2005 Non-Executive Director

Charles-Antoine Janssen

2012 Non-Executive Director

Jean van Rijckevorsel

Non-Executive Director

Albrecht De Graeve

59 2010 Non-Executive Independent Director

Harriet Edelman

57 2012 Non-Executive Independent Director

Jean-Pierre Kinet

2008 Non-Executive Independent Director

Tom McKillop

71 2009 Non-Executive Independent Director

Norman Ornstein

2008 Non-Executive Independent Director

Biographies

Name Description

Gerhard Mayr

Mr. Gerhard N. Mayr serves as Non-Executive Chairman of the Board of U C B SA since May 2012. He has served as Non-Executive Independent Director of the Company since June 14, 2005. He is Member of the Company’s Audit Committee and the Company's Governance, Nomination and Compensation Committee. He received a Master's degree in Chemical Engineering from the Swiss Federal Institute of Technology (Zurich, Switzerland) in 1969, and a Master of Business Administration degree from Stanford University in 1972. In March 2004, he retired as Executive Vice President of pharmaceutical operations at Eli Lilly & Company after 32 years of service. Mr. Mayr is Member of the Board of Lonza Group Ltd (since 2006)., Member of the Board of the Vienna Science, Research and Technology Foundation (since 2002) and Member of the Board of Project Hope, United States (since 2002). He is Member of the circle of patrons of INSEAD Business School (since 2000). Mr. Mayr was previously Member of the board of Alcon, Inc. (2007-2010), Member of the board of OMV AG, Vienna (2002-2009), Member of the board of Bank Austria AG, Vienna (1998-2006), Member of United States - Egypt President’s Council (1999-2004), Member of the board of the European Federation of the Pharmaceutical Industry (1995-1997 and 2000-2002), Chairman of the International Executive Committee of the Pharmaceutical Research Manufacturers of America, Chairman of the Europe Committee of the Pharmaceutical Research Manufacturers of America, Executive Vice President of Eli Lilly & Company with responsibility for global pharmaceutical operations (1999-2004), President of Lilly Intercontinental (1997-1999), President of Lilly International (1993-1997) and joined Eli Lilly in 1972 as Sales Representative.

Roch Doliveux

Dr. Roch Doliveux serves as Executive Director at UCB SA. He no longer serves as Chief Executive Office and Chairman of the Executive Committee of the Company, effective as of January 1, 2015. He is Doctor in Veterinarian Medicine from Maisons-Alfort (France), Mr. Doliveux is also Laureate of the Faculty of Medicine, Creteil, and holds a Masters of Business Administration from INSEAD (France) with distinction. He joined the pharmaceutical industry early, first at Ciba-Geigy (now Novartis) in Switzerland, in Peru and in France, and then at Schering-Plough Corporation in various positions, including President of Schering-Plough International. Then, Roch Doliveux joined the Pierre Fabre group a Chief Executive Officer (CEO) of Pierre Fabre Pharmaceuticals. Mr. Doliveux joined UCB in October 2003 as Director General of the Pharma Sector and Deputy Chairman of the Executive Committee. He became CEO and Chairman of the Executive Committee of UCB on January 1, 2005. He is a member of the Board of Directors of UCB, Member of the Board of Stryker Corporation in the United States, as well as a member of the Board of the European Federation of Pharmaceutical Association (EFPIA), the Innovative Medicines Initiative (IMI) which is a public-private partnership between the European Union and EFPIA, WELBIO (Walloon Institute for Life Lead Sciences), the INSEAD International Council and Chairman of the Caring Entrepreneurship Fund (King Baudouin Foundation). He was awarded the Doctor Honoris Causa degree of the University of Liege (Belgium) in October 2011.

Evelyn Diego du Monceau de Bergendal

Countess Evelyn Diego du Monceau de Bergendal serves as Non-Executive Vice Chairwomen of the Board of U C B SA since June 13, 2006. Ms. du Monceau has graduated in Applied Economics from the Catholic University of Louvain UCL in Belgium (Universite catholique de Louvain). She followed courses in International Relations at the Kennedy School of Harvard University and in Soil Science, Animal Science and Zoology at the Agricultural and Technical College of Farmingdale (New York). She is Member of the Board of UCB since 1984 and has been elected Vice-Chair of the Board since 2006. She also is Chair of the Remuneration and Nomination Committee since 2006. She is Member of the Board of Directors of Financiere de Tubize and member of the Board of Solvay S.A. She is Member of the Nomination and of the Remuneration Committees of Solvay S.A. She is Chairman of the Company's Governance, Nomination and Compensation Committee.

Detlef Thielgen

Mr. Detlef Thielgen serves as Chief Financial Officer since September 1, 200 and Executive Vice President and Member of the Executive Committee since January 2007 of U C B SA. Mr. Thielgen served as Chief Financial Officer of Schwarz Pharma AG and Managing Director of Schwarz Pharma Operations covering the worldwide manufacturing and supply chain functions. He also took on the responsibility of Vice President Finance & Administration/Chief Financial Officer at Schwarz Pharma Inc./States of America.

Anna Richo

Ms. Anna S. Richo has served as Member of the Executive Committee, Executive Vice President and General Counsel of U C B SA since January 1, 2013. She joined UCB from Amgen Inc., where she was Senior Vice President and Chief Compliance Officer. Prior to that, she was Vice President, Law responsible for management of Amgen’s corporate litigation and law department operations, and upon joining Amgen in 2003, she was responsible for corporate law activities. From 1991 - 2003, she was at Baxter Healthcare Corporation, holding a number of positions with increasing responsibility including Vice President, Law for the BioScience business and was previously ChiefLitigation Counsel for the company. Prior to joining Baxter, Ms. Richo was an attorney for The NutraSweet Company, and was an associate with the Chicago-based law firm of Peterson & Ross. Ms. Richo received her Juris Doctor degree from DePaul University, College of Law and her Bachelor of Science degree in Industrial and Labor Relations from Cornell University. She is admitted to practice in Illinois and California. She formerly served on the Board of Directors of Cytyc Corporation a medical diagnostics company, from 1998 - 2003, and was Member of the Audit and Finance Committees.

Fabrice Enderlin

Mr. Fabrice Enderlin serves as Member of the Executive Committee and Executive Vice President Corporate Human Resources & Communication of UCB SA since March 1, 2008. Mr. Enderlin has a Master degree in Political Sciences and a Masters of Business Administration in Human Resources. His interest for Human Resources became obvious when working in 1984, during his university studies, at Mc Donald’s as Store manager. He then started his career as Training & Development Manager for Arcelor in the steel industry. He has experience within the Biopharma world initially with Ciba-Geigy where he joined a production plant in 1991, before supporting the Novartis merger in 1997 as Vice President HR Pharma France. He joined GSK in 2000 leading as Vice President HR France broad change management activities during the merger of the two Anglo-Saxon companies. In 2003, he embraced an international career supporting the fast growth of the vaccines division of GSK as Vice President HR within GSK Biologicals, based in Belgium. Since he joined the Company, he has taken additional responsibilities welcoming, besides the initial HR activities, the operational excellence team, the Global Communication department as well as, more recently, the Corporate Social Responsibility (CSR) area.

Ismail Kola

Dr. Ismail Kola Ph.D. serves as Executive Vice President & President UCB NewMedicines and Member of the Executive Committee of U C B SA since November 2009. Mr. Kola holds a Doctorate in Philosophy in Medicine from the University of Cape Town, South Africa. He also holds a Bachelor of Science from the University of South Africa - UNISA and a Bachelors degree from Rhodes University. He joined the Company from Schering Plough Corporation where he was Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine, Schering-Plough Research Institute, the pharmaceutical research arm of Schering-Plough Corporation, and Chief Scientific Officer, Schering Plough Corporation. He came to Schering-Plough from Merck, where he was Senior Vice President and Site Head, Basic Research. He also chaired Merck's Antibacterial and Antifungal Worldwide Business Strategy Team. Prior to that, he was Vice President, Research, and Global Head, Genomics Science and Biotechnology, with Pharmacia Corporation. Prior to his move to Industry, Ismail was Professor of Human Molecular Genetics, Monash University Medical School and Director of the Research Center for Functional Genomics and Human Disease. He was at Monash for approximately 15 years. He holds Adjunct Professorships of Medicine at Washington University, St Louis, Missouri, United States, and Monash University Medical School, Melbourne, Australia; a Foreign Adjunct Professorship at The Karolinska Institute, Stockholm, Sweden; and is a William Pitt Fellow at Pembroke College, Cambridge University, United Kingdom. He is Member of the Board of Athersys Inc., Biotie Therapies, and Astex Pharmaceuticals.

Iris Loew-Friedrich

Prof. Dr. Iris Loew-Friedrich serves as Executive Vice President Biopharma Development Solutions, Chief Medical Officer and Member of the Executive Committee of U C B SA since March 1, 2008. Prior to taking on her current role in March 2008, Dr. Loew-Friedrich was the Company's Global Head of Development, during which time she oversaw clinical development of neurology and immunology products. From 2001 to 2009, Dr. Loew-Friedrich also served as the head of Global Research and Development for Schwarz Pharma, which the Company moved to acquire in 2006. She was also on the Schwarz Pharma Executive Board. Dr. Loew-Friedrich held several medical and R&D roles, including Vice-President and Head of Global Projects at BASF Pharma, Ludwigshafen, Germany; Vice-President, Head of Global Clinical Management, HMR/Aventis, and Therapeutic Area Head Rheumatology and Bone Diseases, Hoechst/HMR, Bridgewater, New Jersey. Dr. Loew-Friedrich received her medical license and her Doctorate in Philosophy from Frankfurt University, Frankfurt, Germany, in 1985. From 1985 to 1992, Dr. Loew-Friedrich was the staff physician at the Department for Internal Medicine at the Frankfurt University Medical School, with sub-specialties in immunology, nephrology, and transplantation medicine. She is board-certified in internal medicine and olds a professorship at Frankfurt University Medical School.

Mark McDade

Mr. Mark McDade serves as Executive Vice President Established Brands, Solutions and Supply, Member of the Executive Committee of U C B SA since September 16, 2008. He joined the Company as Executive Vice President, Corporate Strategy and Business Development in April 2008. From 2002 until late 2007 he was Chief Executive Officer and Director of PDL BioPharma, Inc. Prior to PDL, he served as Chief Executive Officer of Signature BioScience, Inc. and was previously co-founder and Director of Corixa Corporation, where he served as Chief Operating Officer from September 1994 through December 1998 and as President and Chief Operating Officer from January 1999 until his departure in late 2000. Before Corixa, Mr. McDade was Chief Operating Officer of Boehringer Mannheim - Therapeutics, and prior to that held several positions at Sandoz Ltd. including business development, product management and general management. Mr. McDade received a Bachelor of Arts from Dartmouth College and a Masters of Business Management from Harvard Business School.

Jean-Christophe Tellier

Mr. Jean-Christophe Tellier has been appointed Chief Executive Officer and Chairman of the Executive Committee at UCB SA effective as of January 1, 2015. Before that, he has been Member of the Executive Committee, Executive Vice President and President of European Operations of U C B SA since July 1, 2011. He has joined the Company from Ipsen where he was President & General Manager Ipsen US. His role at Ipsen was to strengthen Ipsen's specialty care business in North America, in the areas of endocrinology and neurology. He joined Ipsen in May 2009. He started his career in 1988 in the marketing department of Synthelabo and joined Ciba France as Group Marketing Manager in 1990 and got various marketing & sales position until leading the Marketing & Sales department. In 1997, following the merger of Ciba and Sandoz to form Novartis, he was appointed Head of the Mass Market Business unit in France until the end of 1999 where he became Chief Operating Officer of Novartis France. From 2003 to mid-2006, JC Tellier was Chief Executive Officer (CEO) of Novartis Pharma Belgium and during his tenure was elected president of Pharma.be, the Pharma trade association. At the end of 2006, he was promoted to Head of the Global Arthritis, Bone and Muscle disease Business Franchise at Novartis Headquarters in Basel, Switzerland. In February 2007, he was appointed Chairman and CEO of Novartis Pharma France and Novartis Group France until mid 2008 when he decided to join MacroGenics Inc., a Maryland-based biotechnology company, as Executive Vice President and Chief Commercial Officer. He is physician specialized in rheumatology (University of Paris V, France) and followed diverse executive training both at INSEAD and Harvard.

Arnoud de Pret Roose de Calesberg

Count Arnoud de Pret Roose de Calesberg serves as Non-Executive Director of U C B SA since June 14, 2005. He is consultant and Commercial Engineer from UCL (Louvain). He started his career as Credit Officer with Morgan Guaranty Trust of New-York (Brussels and Antwerp) in 1971. He became Treasurer and Corporate Finance Manager Cockerill (Liege) in 1978. He joined the Company (Brussels) in 1981 as Chief Financial Officer and Member of the Executive Committee. He became in 1990, Treasurer and Corporate Finance Manager at Societe Generale de Belgique before joining Umicore in 1991 as Chief Financial Officer and Member of the Management Committee until May 2000. He is Member of the Boards of Lesaffre & Cie, Silbelco, Umicore and l'Integrale and of the Supervisory Board of NYSE Euronext. He is Chairman or Member of the Audit Committees of Umicore, Sibelco and NYSE Euronext b.v. and Chairman or Member of the Finance Committees of l'Integrale and Lesaffre & Cie. He holds a degree in Engineering from Catholic University of Leuven (Katholieke Universiteit Leuven). He is Chairman of the Company's Audit Committee.

Peter Fellner

Dr. Peter J. Fellner serves as Non-Executive Director at UCB SA since June 14, 2005. He is currently Chairman of the medical device companies Consort Medical Plc and Optos Plc, and of the biotechnology company, Biotie Therapies Corp. He has also served as Chairman of the United Kingdom (UK) biotechnology company Vernalis plc since April 2003. Mr. Fellner is Vice-Chairman of the United States (US) biotechnology company Astex Pharmaceuticals Inc. and serves as Member of the Novo A/S Advisory Group. He was previously Chairman of the life science companies Acambis plc and of Premier Research Group plc, until each was acquired during 2008. He was Chairman of Celltech Group plc, having previously served as its Chief Executive Officer from 1990 to 2003. He oversaw its development into a UK biotechnology company, and a FTSE 100 constituent, until its acquisition by the Company in 2004. Before Celltech he was he was Director of the Roche U.K. Research Centre from 1984 to 1986 then Chief Executive Officer of Roche UK, from 1986 to 1990. He is Member of the Company's Scientific Committee.

Charles-Antoine Janssen

Mr. Charles-Antoine Janssen serves as Non-Executive Director of U C B SA since April 2012. He has joined the Company in 2001 where he held several management positions at global and local levels. Among other responsibilities he was head of Business Development, General Manager of Austria and India, and most recently managed International Major Markets Operations. Prior to the Company, he worked for Merrill Lynch in London from 1996-2000 where he was Vice-President Equities Research then Vice-President New Derivatives Europe. He holds a bachelor of Laws degree from Brussels University (ULB) and an AMP from Harvard Business School.

Jean van Rijckevorsel

Ms. Jean (Bridget) van Rijckevorsel is Non-Executive Director of U C B SA. She is Member of the Board of Directors of privately owned investment companies.

Albrecht De Graeve

Mr. Albrecht (Bert) De Graeve serves as Non-Executive Independent Director of U C B SA since April 29, 2010. Mr. De Graeve is Chief Executive Officer of the Bekaert Group since May 2006. From 2002 until May 2006 he was Chief Financial and Administration Officer and General Secretary of the Group. He started his career in 1980 with Arthur Andersen & Co and joined Alcatel Bell in 1982. In 1991 he became General Manager Shanghai Bell Telephone Equipment Mfg. Cy in Shanghai. In 1994 he was appointed Vice President, Director Operations, Alcatel Trade International and later Director International Affairs, Alcatel Alsthom in Paris. In 1996 he became Managing Director of the Flemish Public Radio & TV Broadcaster (VRT). Mr. De Graeve holds a Master in Law from the University of Ghent (1980), studied Financial Management at IPO (Antwerp) and became Master in Tax Management at VLEKHO (Brussels). Mr. De Graeve is Member of the International Business Leaders' Advisory Council for the Mayor of Shanghai (IBLAC), President of the Flanders-China Chamber of Commerce, Member of the Advisory Board of the Conference Board China Center for Economics and Business in Beijing, Member of the Board of Directors of UCB and Member of the Board of the Concours Reine Elisabeth. He is Member of the Company's Audit Committee.

Harriet Edelman

Ms. Harriet Edelman serves as Non-Executive Independent Director of U C B SA since April 2012. She is currently Vice Chairman of Emigrant Bank. She has been with the bank since 2008 and, prior to that, was employed at Avon Products, Inc. She held several roles at Avon Products throughout her career, including Senior Vice President & Chief Information Officer, Senior Vice President, Global Supply Chain and several prior executive positions in Marketing, Sales and Customer Service. Ms. Edelman serves as Director of Brinker International, Inc. and Ariba, Inc. She also serves on the Board of Trustees of Bucknell University and the New York Blood Center. Ms. Edelman holds a Bachelor degree from Bucknell University and a Master of Business Administration in Marketing from Fordham University.

Jean-Pierre Kinet

Prof. Jean-Pierre Kinet serves as Non-Executive Independent Director of U C B SA since April 24, 2008. He has been Director of the Company since April 24, 2008. He has been Professor of Pathology at Harvard Medical School since 1995, and Director of the Division of Allergy and Immunology at the Beth Israel Deaconess Medical Center since 2000. He served as Head of the Molecular Allergy and Immunology section of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health from 1989 to 1995. He is former practicing physician and earned his Doctorate of Medicine from the Universie de Liege. He holds 13 issued patents and is founder and Board Member of AB Science and a number of other biopharmaceutical companies. He is Member of the Company’s Scientific Committee.

Tom McKillop

Dr. Tom McKillop Ph.D. serves as Non-Executive Independent Director at U C B SA since November 6, 2009. He was educated at Irvine Royal Academy, Glasgow University and Centre de Mecanique Ondulatoire Appliquee (Paris). He joined ICI's Corporate Research Laboratory at Runcorn in 1969 and his research interests ranged from synthetic chemistry to quantum mechanics and molecular biology. In 1975 he moved to ICI Pharmaceuticals Division and held a number of increasingly senior Research and Development positions until his appointment in 1989 as Technical Director and Deputy Chairman of ICI Pharmaceuticals, a role in which he had global responsibility for Research, Development, Medical and Production. In 1994, he was appointed Chief Executive Officer of Zeneca Pharmaceuticals - Zeneca having demerged from ICI in 1993 - and, on completion of the merger of Astra and Zeneca in April 1999, he became Chief Executive of AstraZeneca PLC, a position he held until retiring on December 31, 2005. His industry activities included periods as Chairman of the British Pharma Group, President of the European Federation of Pharmaceutical Industries and Associations, Chairman of the Pharmaceutical Industry Task Force, and as Member of The European Round Table of Industrialists and the European Financial Round Table. Currently Sir Tom was president of The Science Council from 2007 -2011 and is currently Non-Executive Director of Almirall SA, Evolva Holding SA and Theravectys SAS. He has previously served as Chairman of the Royal Bank of Scotland, and as Non-Executive Director of BP plc, Amersham International plc (now GE Healthcare) and Lloyds TSB plc. During his career Sir Tom has received many scholarly awards and fellowships and was knighted in 2002 for services to the pharmaceutical industry. He holds a Bachelor of Science in Chemistry and Doctorate in Philosophy in Chemistry both from the University of Glasgow. He is Member of the Company's Governance, Nomination and Compensation Committee.

Norman Ornstein

Dr. Norman J. Ornstein Ph.D. is Non-Executive Independent Director of U C B SA since April 24, 2008. He is resident scholar at the American Enterprise Institute for Public Policy Research based in Washington D.C., United States. He serves as senior counselor to the Continuity of Government Commission and as election analyst for CBS News. He writes in several United States newspapers and other publications related to United States politics. Mr. Ornstein has a Bachelor of Arts from the University of Minnesota, from which he also received an honorary Doctor of Laws degree, and a Master of Arts and Doctorate in Philosophy from the University of Michigan. He served as Member of the Board of Public Broadcasting Service (PBS) and is currently on the Board of Directors of the Campaign Legal Center as well as of the Board of Trustees of the United States Capitol Historical Society and the Center for United States Global Engagement.
Search Stocks